Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA 73rd Annual Section of Antitrust Law Spring Meeting
Speaking Engagement
Antitrust
CompLaw Nordic 2025
Sponsorship
Antitrust
GCR Live Cartels: 2025
Speaking Engagement
Antitrust
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2025
Speaking Engagement
Antitrust
2025 Why Antitrust: Everything You Need to Know About a Career in Antitrust Law
Speaking Engagement
Antitrust
Competition Law Developments in Germany: Three Things We Are Watching
Axinn Viewpoints
Antitrust
Noerr Competition Day 2025
Speaking Engagement
Antitrust
Who’s Blocking Me? Competition Law Issues With Healthcare Information Blocking
Axinn Viewpoints
Antitrust
Daniel Oakes, Tiffany Rider, and Lindsey Strang Aberg Win “Law360 Distinguished Legal Writing Award”
Awards & Recognitions
Antitrust